Amanda L Woodward

Liquid Amber, 4045 Youngstown Kingsville Rd, Cortland, US.

2 papers in the library · publishing 2026

Papers

At-Home Telehealth-Supported Subcutaneous Ketamine Therapy in Adults With Moderate to Severe Depression, Anxiety, or PTSD: A Real-World Observational Study of Safety, Feasibility, and Clinical Outcomes in a Large, Heterogeneous Cohort in the United States.

Journal of medical Internet research June 17, 2026 Acacia C Parks, Amanda L Woodward, Robert D Henry et al.

A large analysis of 3,870 patients with moderate-to-severe depression, anxiety, or PTSD who used a telehealth program for at-home subcutaneous ketamine found significant symptom reductions after about six weeks. Depression scores on the PHQ-9 fell from 14.6 to 6.3, anxiety scores on the GAD-7 from 13.1 to 6.1, and PTSD scores on the PCL-5 from 46.7 to 27.5, all with large effect sizes. Over 80% of patients achieved a clinically meaningful improvement. Adverse events were low (2.8%-3.2%), and no serious complications occurred. The results suggest that supervised at-home subcutaneous ketamine is a safe and effective option that could expand access to rapid-acting treatment.

DOI: 10.2196/92647 Full text

At-Home Telehealth-Supported Subcutaneous Ketamine Therapy for Depression, Anxiety, and PTSD: A Real-World Observational Study of Safety, Feasibility, and Effectiveness in a Large Cohort (Preprint)

Acacia C Parks, Amanda L Woodward, Robert D Henry et al.

A telehealth-supervised at-home subcutaneous ketamine protocol for moderate-to-severe depression, anxiety, and PTSD was safe, feasible, and highly effective. Among 3,870 patients, symptom scores dropped from moderate-to-severe to mild or subthreshold ranges after about six weekly sessions: depression scores fell from 14.64 to 6.30, anxiety from 13.06 to 6.09, and PTSD from 46.7 to 27.5, with large effect sizes. Clinically meaningful improvement occurred in 80% to 84.6% of patients, depending on condition. Adverse events were low (2.8%–3.2%), and no serious complications were reported. The model offers a lower-cost, high-bioavailability alternative to in-clinic ketamine infusions.

DOI: 10.2196/preprints.92647